Novel Treatment Options in Mantle Cell Lymphoma With Gilles Salles, MD, PhD

An aggressive form of B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL) is a challenging disease to treat, with a median overall survival of 6 to 7 years. Even in patients who achieve a complete response, recurrence and relapse are still frequent. In this episode of Oncology Data Advisor, Gilles Salles, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, joins i3 Health for a discussion that covers the efficacy of newly developed Bruton tyrosine kinase (BTK) inhibitor and chimeric antigen receptor (CAR) T-cell therapies, the management of adverse events associated with these treatments, updates on ongoing research, and advice for clinicians as they seek to optimize outcomes for patients with MCL.

TARGET AUDIENCE

Hematologists, oncologists, hematology/oncology advanced practitioners, and other health care professionals involved in the treatment of patients with MCL.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

1.) Assess efficacy and safety of novel BTK inhibitor therapy for MCL
2.) Assess efficacy and safety of CAR T-cell therapy for MCL